

Common Risk Factors for AKI in our Setting: Can We Prevent Them?



Chris Esezobor

Professor: College of Medicine University of Lagos

Consultant Paediatrician: Lagos University Teaching Hospital

Objectives & Outline

Objectives


- To highlight the definition of AKI
- To review the consequences of AKI
- To identify the common causes of AKI in our region: exposures and susceptibility
- To identify ways to prevent AKI

Outline

- What is AKI?
- How common is AKI?
- What are the implications of AKI
- What are the common causes of AKI?
- Can we prevent AKI?

What is AKI?

- It is a clinical entity in which there is a sudden deterioration of kidney function (<7 days)
 - Depicted by rise in serum creatinine or fall in urine output occurring




AKD= kidney disease <3 months
CKD= kidney disease >3 months


KDIGO Staging of AKI

Stage	Serum Creatinine	Urine Output
1	1.5–1.9 times baseline OR ≥ 0.3 mg/dl (≥ 26.5 μ mol/l) increase	<0.5 ml/kg/h for 6–12 hours
2	2.0–2.9 times baseline	<0.5 ml/kg/h for ≥ 12 hours
3	3.0 times baseline OR Increase in serum creatinine to ≥ 4.0 mg/dl (≥ 353.6 μ mol/l) OR Initiation of renal replacement therapy OR , In patients <18 yr, decrease in eGFR to <35 ml/min per 1.73 m ²	<0.3 ml/kg/h for ≥ 24 hours or anuria ≥ 12 hours

AKI: How common is it?



No. studies	154	112	108	108	189
No. patients	3,585,911	3,303,992	3,281,715	3,281,715	29,400,495



Neonatal AKI


Susantitaphong et al. CJASN 2013;8:1482-1493

Jetton et al. Lancet Child Adolesc Health 2017; 1: 184–94

AKI: Common causes

- Prerenal causes
- Intrinsic causes
- Post renal causes

	Children n=1643	Adults n=993
Infections (>80-90% septicemia)	380 (23%)	274 (28%)
Glomerular diseases (mostly nephrotic syn & AGN)	350 (21%)	76 (8%)
Nephrotoxins (mostly malaria)	270 (16%)	182 (18%)
Intravascular depletion/hypotension (mostly gastro)	174 (11%)	50 (5%)
Obstructive uropathy (PUV and kidney stones)	146 (9%)	46 (5%)
Vascular disease or hemolysis (HUS)	116 (7%)	11 (1%)
Obstetric/gynaecological (septic abortion, pre-eclampsia, PPH)	-	157 (16%)
Perinatal asphyxia	27 (2%)	-



Oluwo et al: Lancet Glob Health 2016; 4: e242–50


Exposures v
Susceptibilities

Exposures	Susceptibilities
Sepsis	PUV other CAKUT
Malaria	Dehydration or volume depletion
Gastroenteritis	Young age
Burns	Chronic kidney disease
Perinatal asphyxia	Cancer
Shock	Anaemia
Major surgeries	ACEI/ARB
Nephrotoxins, radiocontrast	Chronic diseases

KDIGO: Kidney Int 2012

AKI: Consequences


Children and adults worldwide



	Overall (KDIGO-equivalent)	Stage 1 (Risk)	Stage 2 (Injury)	Stage 3 (Failure)	Dialysis Requirement
No. studies	110	26	25	25	31
No. patients with AKI	429,535	8,226	42,354	42,354	6,534

	Crude odds ratio or parameter estimate (95% CI)	p value	Adjusted odds ratio or parameter estimate (95% CI)	p value
Mortality	7.5 (4.5-12.7)	<0.0001	4.6 (2.5-8.3)*	<0.0001
Length of stay (days)	14.9 (11.6-18.1)	<0.0001	8.8 (6.1-11.5)†	<0.0001

Children and adults in Africa



Neonates

Susantitaphong et al. CJASN 2013;8:1482-1493
 Jetton et al. Lancet Child Adolesc Health 2017; 1: 184-94
 Oluwo et al: Lancet Glob Health 2016; 4: e242-50

AKI Consequences: Others

- Increased cost of hospitalisation
- Higher rates of adverse cardiovascular outcomes: **hypertension, heart failure and myocardial infarction**
- Higher rates of adverse kidney outcome: **albuminuria, CKD**

Criterion	Mean Unadjusted Increase in Total Cost (\$)	Mean Adjusted (Marginal) Increase in Total Cost (\$)
↑ SCr \geq 0.3 mg/dl	\$ 8,902	\$ 4,886
↑ SCr \geq 0.5 mg/dl	\$12,656	\$ 7,499
↑ SCr \geq 1.0 mg/dl	\$21,475	\$13,200
↑ SCr \geq 2.0 mg/dl	\$33,161	\$22,023
↑ SCr by 25%	\$ 7,469	\$ 3,721
↑ SCr by 50%	\$10,125	\$ 5,510
↑ SCr by 100%	\$15,192	\$ 8,999
↑ SCr by 50% to a minimum peak of 2.0 mg/dl	\$19,517	\$11,719
↑ SCr \geq 0.5 mg/dl with baseline SCr < 2.0 mg/dl or ↑ SCr \geq 1.0 mg/dl with baseline SCr \geq 2.0 and < 5.0 mg/dl	\$13,451	\$ 7,982


Chertow et al JASN 2005
 Oduyayo et al JASN 2017
 Parr et al Kidney Int 2018
 Hsu et al JASN 2016

AKI: Can it be prevented?

- **General health promotion:** Appropriate housing, potable water, safe disposal of waste, antenatal care; avoidance of overcrowding
- **Specific protection:** use of insecticide treated net; immunisations; referral of high risk pregnancy; skilled manpower at delivery; safe abortion
- **Early diagnosis and treatment:** ORS for gastroenteritis, prompt diagnosis and treatment of malaria and other infections; trained sonographers to detect CAKUT
- Avoidance of nephrotoxic medications

AKI Prevention: Malaria

- Sleeping under insecticide treated net
- Prompt detection of malaria
- Appropriate treatment of malaria with ACT
- Paracetamol??



Clinical Infectious Diseases

MAJOR ARTICLE

 **IDSA**
Infectious Diseases Society of America

 **hivma**
hiv medicine association

 **OXFORD**

Acetaminophen as a Renoprotective Adjunctive Treatment in Patients With Severe and Moderately Severe Falciparum Malaria: A Randomized, Controlled, Open-Label Trial

Katherine Plewes,^{1,2,3} Hugh W. F. Kingston,^{1,4} Aniruddha Ghose,⁵ Thanaporn Wattanakul,¹ Md. Mahtab Uddin Hassan,⁵ Md. Shafiul Haider,⁵ Prodip K. Dutta,⁶ Md. Akhterul Islam,⁷ Shamsul Alam,⁸ Selim Md. Jahangir,⁹ A. S. M. Zahed,⁵ Md. Abdus Sattar,⁵ M. A. Hassan Chowdhury,⁵ M. Trent Herdman,¹ Stije J. Leopold,^{1,2} Haruhiko Ishioka,^{1,10} Kim A. Piera,⁴ Prakaykaew Charunwatthana,^{1,10} Kamolrat Silamut,¹ Tsin W. Yeo,^{4,11} Sue J. Lee,^{1,2} Mavuto Mukaka,^{1,2} Richard J. Maude,^{1,2,12} Gareth D. H. Turner,^{1,2} Md. Abul Faiz,¹³ Joel Tarning,^{1,2} John A. Oates,¹⁴ Nicholas M. Anstey,⁴ Nicholas J. White,^{1,2} Nicholas P. J. Day,^{1,2} Md. Amir Hossain,⁵ L. Jackson Roberts II,¹⁴ and Arjen M. Dondorp^{1,2}

Plewes et al. CID 2018; Google


AKI Prevention: Gastroenteritis



Google

Maternal and Newborn Care

- High-quality antenatal care
 - Identify high-risk mother for appropriate referral
 - Avoid nephrotoxic medications in pregnancy: alcohol, ACEI/ARBS
 - Prenatal detection of CAKUT
- Health provider at delivery
 - prevent many cases of avoidable prenatal asphyxia
 - Prevent postpartum haemorrhage and sepsis
- Aminophylline for asphyxiated neonate



Bhatt et al. Arch Dis Child
2019; Google

Way to
prevent
(hospital
acquired)
AKI

A useful bedside aide memoir is STOP AKI

STOP AKI

SEPSIS – Screen/treat

TOXINS – avoid

OPTIMIZE BP/VOLUME STATUS

PREVENT HARM

- Identify cause/urinalysis
- Treat complications
- Review medication doses
- Review fluid prescription



Questions and Comments

Conclusion

- AKI is common among hospitalised patients
- It carries significant short and long term consequences
- A substantial number of AKI can be prevented by simple, low-cost and integrated strategies



CHALLENGES WITH PERITONEAL DIALYSIS FLUID EXCHANGE


NR. TIJJANI RAIMI



INTRODUCTION

- Peritoneal dialysis is a type of dialysis that uses the peritoneum as the membrane through which fluid and dissolved substances exchange with blood
- PD has equivalent efficacy and comparable to IHD/CRRT with regards to mortality and early recovery of renal function
- In low resource setting PD offers potential benefit that are hard to over look

Peritoneal Dialysis



Contraindications of PD

- Intra abdominal infection–TB peritonitis
- Presence of hernia
- Distended bowel loop
- Features of peritoneal adhesion
- Diaphragmatic peritoneal–pleural connection
- Peritonitis/abdominal wall cellulitis
- AKI in pregnancy

PD FLUID

In low resource setting PD fluid is often reconstituted using Ringers lactate and Glucose

DEXTROSE

- 2.5 L- 1.5% Dextrose
- 4.5L – 2.5% Dextrose
- 8.5L – 4.25% Dextrose

Buffer; Lactate or Bicarbonate

In some case;

Potassium – added if patient have hypokalaemia

Insulin- added if patient is diabetes in some cases

Types of Catheters

- Best design catheter for PD should;
 - Give maximum inflow and outflow
 - Discourage infection
- Types
 - Flexible catheter- Tenckhoff
 - Rigid catheter
 - **Improvised**; NG tube, rubber catheter, intercostal drainage catheter

CHALLENGES

- Slow dialysate inflow and outflow drainage, often occurs when rigid catheters are used
 - Reposition the patient and check tubing and catheter for kink
 - Flush the catheter with saline
 - Heparin solution can be use to flush if clot or fibrin is present in the catheter
- Hyperglycaemia due to added glucose
 - Add insulin to the dialysate as prescribed

CHALLENGES

- Poor patient compliance – due to higher number of connections disconnections and increase intra abdominal pressure, hernia and PD leak causing discomfort.
- Solution:
 - Patient education
 - Assessment of abdominal capacity
 - Reduce the volume of inflow PD fluid
 - Use of appropriate catheter size

CONCLUSION

- Long time outcome associated with PD are good
- It is an effective alternative to HD especially in low resource setting
- It is particularly good in patients who are new to renal replacement therapy and have less comorbidity.

REFERENCES

- Akonur, A., Firanek, C. A., Gellens, M. E., Hutchcraft, A. M., Kathuria, P., & Sloand, J. A. (2015). *Volume-based peritoneal dialysis prescription guide to achieve adequacy targets*. *18*, 1–8. <https://doi.org/10.3747/pdi.2014.00255>
- Cullis, B., Al-hwiesh, A., Kilonzo, K., Mcculloch, M., Niang, A., Nourse, P., Parapiboon, W., Ponce, D., & Finkelstein, F. O. (2020). *ISPD guidelines for peritoneal dialysis in acute kidney injury : 2020 update (adults)*. <https://doi.org/10.1177/0896860820970834>
- Davies, S. J. (2013). challenges. *Nature Publishing Group*, *9(7)*, 399–408. <https://doi.org/10.1038/nrneph.2013.100>
- Morelle, J., Stachowska-pietka, J., Carl, O., Mehrotra, R., Arteaga, J. De, & Davies, S. (2021). *ISPD recommendations for the evaluation of peritoneal membrane dysfunction in adults : Classification , measurement , interpretation and rationale for intervention*. <https://doi.org/10.1177/0896860820982218>

REFERENCES

- Ponce, D., & Balbi, A. (2017). Acute PD_ Evidence, Guidelines, and Controversies☆. *Seminars in Nephrology*, 37(1), 103–112. <https://doi.org/10.1016/j.semnephrol.2016.10.011>
- Roumeliotis, A., Roumeliotis, S., Leivaditis, K., & Salmas, M. (2020) . APD or CAPD : one glove does not fit all. *International Urology and Nephrology*, 0123456789. <https://doi.org/10.1007/s11255-020-02678-6>
- Who. (2011). *Fact Sheet: Disaster Risk Management for Health Key points*. May, 1–2. http://www.who.int/hac/events/drm_fact_sheet_communicable_diseases.pdf

THANK YOU ALL

Improvised and acceptable PD Consumables

Chris Esezobor

Professor: College of Medicine University of Lagos

Consultant Paediatric Nephrologist: Lagos University Teaching Hospital

Peritoneal Dialysis Fluids

- Should achieve ultrafiltration, clearance of solutes and preserve peritoneal membrane integrity
- **3 major components:**
 - Osmotic agents: Glucose, icodextrin, amino acids
 - Buffers: lactate, bicarbonate
 - Electrolytes: Sodium, calcium, magnesium, **no potassium**

PD Fluids & Ringers Lactate

	BicaVera	Balance	Gambrosol	Physioneal	Ringers Lactate
Sodium	132	134	132	132	130
Chloride	104.5	100.5	96	101	109
Calcium	1.75	1.25/1.75	1.75/1.35	1.75	1.5
Magnesium	0.5	0.5	0.25	0.25	0
Lactate	0	35	40	10	28
Bicarbonate	34	0	0	25	0
Osmolality	358-511	358-511	356-483	344-484	273
Potassium	0	0	0	0	4.0
pH	7.4	7.0	5.5-6.5	7.4	6.4

PD Fluid: Alternatives

- A. **1.5% 'PD' Fluid** = Ringer's lactate [500 ml] +
50% Dextrose water [15 ml]

- B. **2.3% 'PD' Fluid** = Ringer's lactate [500 ml] +
50% Dextrose water [23 ml]

- C. **4.25% 'PD' Fluid** = Ringer's lactate [500 ml] +
50% Dextrose water [42.5 ml]

Adding glucose to ringer's lactate makes it similar to most commercial PD fluids in many important respect

PD Fluids: Alternatives



Ringer's Lactate



50% Dextrose water



Potassium chloride and heparin




PD Connectology: Alternatives





PERITONEAL DIALYSIS ASSOCIATED INFECTION

Dr. YEMI R. RAJI, MBChB, MSc, FMCP
*SENIOR LECTURER & CONSULTANT
NEPHROLOGIST
DEPARTMENT OF MEDICINE,
COMUI & UCH IBADAN*



OBJECTIVES

- ❖ To appreciate the magnitude of the infection problems associated with PD catheter use
- ❖ Highlight possible risk factors for PD Catheter infections
- ❖ Understand the diagnosis and management of PD catheter associated infection (exit and tunnel and

OUTLINE

- ❖ Introduction
- ❖ Burden of PDAI
- ❖ Spectrum of PDAI
- ❖ Treatment of PDAI
- ❖ Prevention
- ❖ Summary and conclusion
- ❖ Questions and answers

INTRODUCTION I


- The functionality of PD Catheter is key to effective PD
- However, the use of PD catheter could be associated with various complications
- Broadly classified as non-infectious and infectious PD catheter complications
- Non-infectious catheter complications – obstruction, dislocation, leakage (30-40%)
- Infectious complications – Exit Site Infection (ESI), subcutaneous Tunnel I (TI) and Peritonitis (50-65%)

INTRODUCTION

- Exit Site Infection (ESI) and Tunnel Infection (TI) pose little risks
- However, the possibility of them leading to PD peritonitis demands paying careful attention to them
- It is estimated that 12% of cases of ESI and TI result in PD peritonitis.

RISK FACTORS FOR PDAI

- ESI and TI are significant risk factors for PD associated Peritonitis
- Age, Family income, Education status, Poor hygiene
- Hot and Humid Tropical climate
- Type of PD catheter (1 cuff or 2 cuffs)
- PD Catheter Technique (exit pre-sternal or abdominal)
- Diabetes mellitus, hypoproteinemia
- Type of PD treatment - APD,
- Types of PD solution (acidic P_H and high glucose vs Neutral P_H and low glucose PD fluids)
- Nasal carriage of bacteria (MRSA)



EXIT SITE INFECTION (ESI)

- Approximately one-fifth of peritonitis is associated with ESI
- **ESI is characterised by drainage of pus/blood from the catheter exit and may be associated with redness, tenderness, swelling and overgrowth of granulation tissues in the acute phase.**
- Chronic ESI may be associated with excess granulation tissue and crust in addition to redness and tenderness.
- Incidence – One episode per 24-48 patient months
- ESI is predominantly caused by *S. aureus* and Gram negative organisms, particularly



PRESENTATION OF ESI

- Grade 1 – Area of redness around the exit site
- Grade 2 – Area of redness and small exudate around the exit site
- Grade 3 – Frank pus draining from the exit site
- Grade 4 – Abscess at the exit site
- Grade 5 – Redness, tenderness and subcutaneous swelling along the catheter length – Tunnel Infection

TREATMENT OF ESI


- Staphylococcus aureus – Flucloxacillin 250mg qds and Rifampicin 600mg PO daily for 2 weeks
- MRSA – Vancomycin 30mg/kg IP once a week for 2-4 weeks
- Staphylococcus Epidemidis – Flucloxacillin 250mg qds PO 10-14 days
- Pseudomonas Spp – Ciprofloxacin 500mg b.d and/or Gentamycin 0.6mg/kg daily for 3 weeks
- With topical antibiotic – mupirocin

TUNNEL INFECTION

- TI is infection along the PD catheter within the subcutaneous tissue
- TI may be present as erythema, edema, or tenderness over the subcutaneous pathway but is often clinically occult,
- Incidence – 0.11 – 0.22 per patient year – clinical diagnosis
– 0.35 per patient year – USS diagnosis
- Associated with PD peritonitis in 15 – 25% of patients
- Treatment with appropriate antimicrobial based on



OVERVIEW OF ESI & TI TREATMENT



PERITONITIS 1

- Peritoneal dialysis (PD)-associated peritonitis – Inflammation of the peritoneal membrane and it is a serious complication of PD.
- Leading cause of **hospitalization, catheter loss and a risk of death among PD patients.**
- The overall rate PDAI is between 0.24 to 1.66 episodes per patient year on dialysis
- PD peritonitis usually has an excellent prognosis with resolution within days but it can lead occasionally to the much dreaded **Sclerosing Encapsulated Peritonitis (SEP)**, if not promptly detected and treated

PERITONITIS 2

- Although several organisms are involved in causing PD associated infections (PDAI), **coagulase negative staphylococci (CoNS)** appears to be the most common
- However, rare forms of PD infection, for example, rapidly growing non-tuberculous mycobacterium are associated with catheter loss (80%) and significant mortality (40%)

PERITONITIS 3

- May be characterized by pain with or without purulent PD effluent
- **Diagnosed when at least two of the following are present:**

1. clinical features consistent with peritonitis, that is, abdominal pain and/or cloudy dialysis effluent;
2. dialysis effluent white cell count $> 100/\mu\text{L}$ or $> 0.1 \times 10^9/\text{L}$ (after a dwell time of at least 2 h), with $> 50\%$ polymorphonuclear leukocytes (PMN);

3. positive dialysis effluent culture



TREATMENT OF PD ASSOCIATED PERITONITIS




Figure 1. The algorithm of initial management for PD patients presenting with a clinical diagnosis of peritonitis. PD: peritoneal dialysis.

INDICATIONS FOR PD CATHETER REMOVAL IN PD CATHETER ASSOCIATED INFECTION

- Catheter infection associated with peritonitis
- Infection of the inner cuff of the catheter
- Sepsis caused by catheter infection (rare)
- Catheter infections not responding to prolonged antibiotics
- Recurrent infection (ESI, TI and Peritonitis)
- Pseudomonas aeruginosa or Fungal TI or peritonitis

PREVENTION

- In order to obtain a reduction of the complications, achieve prolonged catheter duration and a better quality of life for PD patients, the surgical technique requires strict adherence to a standardized procedure and a dedicated team
- Action to decrease the risk of PDAI should start in the pre-catheter insertion phase – Patient Education, reduce nasal carriage of bacteria, PD staff training etc
- Improved diagnosis, increased awareness of causative agents in addition to other measures will facilitate prompt management of PDAI and salvage of PD modality

SUMMARY

- ❖ PDAI is major problem among patients on PD
- ❖ It is associated with poor outcomes (morbidity and mortality) and a major cause of transfer to haemodialysis
- ❖ ESI and TI are risk significant risk factors for PD associated peritonitis
- ❖ Prompt diagnosis and treatment of PDAI is key to a favourable outcome
- ❖ Patient education and staff training are important aspects of prevention strategies

REFERENCES – SOME

- Flanigan M, Gokal R. Peritoneal catheters and exit-site practices toward optimum peritoneal access: a review of current developments. *Peritoneal Dialysis International*. 2005 Mar;25(2):132–9.
- ISPD Guideline 2022
- Bieber S, Mehrotra R. Peritoneal dialysis access associated infections. *Advances in Chronic Kidney Disease*. 2019 Jan 1;26(1):23–9.
- Bieber S, Mehrotra R. Peritoneal dialysis access associated infections. *Advances in Chronic Kidney Disease*. 2019 Jan 1;26(1):23–9.

NA GO DE

